HTR1F: IHC Expression in Cancer and Radioligand Target Profile
HTR1F, 5-hydroxytryptamine receptor 1F, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, HTR1F staining is highest in skin cancer (90% of samples positive), head and neck cancer (75% of samples positive) and cervical cancer (82% of samples positive). Evidence on whether HTR1F internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is HTR1F the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze HTR1F freeIs HTR1F a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in skin cancer, 90% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
HTR1F IHC staining by cancer type
Protein expression of HTR1F across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Skin Cancer | 0.80 | High | 90% |
| Head and Neck Cancer | 0.58 | High | 75% |
| Cervical Cancer | 0.55 | High | 82% |
| Bladder Cancer | 0.52 | High | 91% |
| Testicular Cancer | 0.47 | Medium | 100% |
| Colorectal Cancer | 0.42 | Medium | 91% |
| Gastric Cancer | 0.33 | Medium | 73% |
| Lung Cancer | 0.33 | Medium | 46% |
| Ovarian Cancer | 0.31 | Medium | 58% |
| Neuroendocrine Tumors | 0.25 | Medium | 75% |
| Liver Cancer | 0.24 | Medium | 55% |
| Breast Cancer | 0.22 | Medium | 67% |
| Thyroid Cancer | 0.22 | Medium | 67% |
| Pancreatic Cancer | 0.22 | Medium | 67% |
| Prostate Cancer | 0.22 | Medium | 67% |
| Melanoma | 0.14 | Low | 33% |
| Endometrial Cancer | 0.12 | Low | 27% |
| Kidney Cancer | 0.08 | Low | 25% |
| Glioma | 0.06 | Low | 18% |
| Lymphoma | 0.03 | Low | 8% |
Is HTR1F internalized?
Uncertain. Insufficient literature found.
HTR1F clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for HTR1F yet. Search ClinicalTrials.gov for HTR1F trials.
HTR1F normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See HTR1F in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
HTR1F gene essentiality (DepMap)
CRISPR knockout effect across 1232 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related skin cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · B7-H3 (CD276) · HER2 (ERBB2) · ITGAV · ITGB6
See all radioligand therapy targets in skin cancer.
See how HTR1F ranks against 15,000 targets for your indication.
Analyze HTR1F freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.